Moreover, we show that a combined application of Jak2 inhibitors with Aurora kinase inhibitors recapitulates the effects observed for CEP701 and might be beneficial for the treatment of MPN patients if CEP701 fails clinical approval. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.